New drug combo aims to stop blood Cancer's return after transplant
NCT ID NCT06498973
Summary
This early-stage study is testing whether a two-drug combination is safe and can help prevent cancer from coming back in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after they receive a stem cell transplant from a donor. The treatment involves tagraxofusp, which targets cancer cells, and azacitidine, which helps the bone marrow make healthy blood cells. The main goal is to find the safest and most effective dose to give patients for up to six months after their transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.